Hereditary Angioedema Therapeutics Market Outlook Highlights The Next Major Growth Opportunities
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Hereditary Angioedema Therapeutics Market Size Forecast: How Large Could The Market Become By 2030?
The market for hereditary angioedema therapeutics has experienced significant expansion in recent years. Projected to rise from $7.77 billion in 2025 to $9.27 billion in 2026, it reflects a compound annual growth rate (CAGR) of 19.3%. This historical growth has been driven by factors such as restricted understanding of HAE, a reliance on hospital-centered treatment, a limited number of authorized therapeutic choices, dependence on intravenous delivery methods, and low rates of diagnosis due to the condition’s rarity.
The market for hereditary angioedema therapeutics is projected to experience significant expansion over the coming years. By 2030, its value is anticipated to reach $19.03 billion, driven by a compound annual growth rate (CAGR) of 19.7%. This forecasted growth is fueled by several factors, including the increasing use of recombinant C1 esterase inhibitors, a shift toward subcutaneous delivery methods, a rise in prophylactic therapy adoption, the growth of specialty pharmacy channels, and heightened investment in rare disease research. Key trends shaping the market during this period involve the development of personalized therapies, a higher number of orphan drug approvals, progress in subcutaneous drug delivery systems, the creation of on-demand treatment options, and the broadening of hospital and retail pharmacy networks.
Download A Free Sample Report For Comprehensive Market Insights:
Hereditary Angioedema Therapeutics Market Growth Drivers And Industry Catalysts
The rising levels of healthcare spending are anticipated to propel the hereditary angioedema therapeutics market forward in the coming years. Healthcare expenditure is defined as the overall volume of resources, including financial funds, allocated to medical goods and services within a defined timeframe in a specific region. As healthcare spending increases, more resources become available for supporting research and development efforts aimed at uncovering the root causes of hereditary angioedema and creating innovative treatments. As an example, data from the Centers for Medicare & Medicaid Services (CMS), a federal agency in the United States, shows that in June 2025, National Health Expenditure (NHE) rose by 7.5% to $4.9 trillion in 2023, equating to $14,570 per person, and representing 17.6% of the Gross Domestic Product (GDP). Additionally, hospital expenditures saw a 10.4% increase, reaching $1,519.7 billion in 2023, which is notably faster than the 3.2% growth observed in 2022. Consequently, this upward trend in healthcare spending is fueling expansion in the hereditary angioedema therapeutics market.
Hereditary Angioedema Therapeutics Market Segment Analysis: What Are The Major Market Categories?
The hereditary angioedema therapeutics market covered in this report is segmented –
1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Prophylaxis, On-Demand
Hereditary Angioedema Therapeutics Market Trends Influencing Long-Term Demand
Key industry participants in the hereditary angioedema (HAE) therapeutics market are actively designing novel therapies, specifically oral plasma kallikrein inhibitors, aimed at improving disease control and delivering effective, on-demand relief from HAE attacks, which ultimately boosts patient outcomes and quality of life. These oral plasma kallikrein inhibitors are administered by mouth and function by suppressing the plasma kallikrein enzyme, reducing the intensity of hereditary angioedema episodes. As an example, in September 2024, KalVista Pharmaceuticals, a biopharmaceutical firm headquartered in the United States, obtained US Food and Drug Administration acceptance of its New Drug Application for Sebetralstat, which is intended to provide HAE patients with a more accessible, non-invasive treatment option compared to intravenous or subcutaneous injections. This product addresses the increasing need for rapid, potent oral therapies that can be used right away during an HAE attack.
Hereditary Angioedema Therapeutics Market Leading Companies Driving Competitive Growth
Major companies operating in the hereditary angioedema therapeutics market are Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., Dyax Corp., Pharvaris N.V., Kedrion Biopharma Inc., Shire Pharmaceuticals, Octapharma AG, Pharmalink AB, Sobi AB, OctoPharma USA, HAE Pharma, Argenx SE, ImmunoGen Inc., Ionis Pharmaceuticals (for pipeline HAE therapies), PharmAthene Inc., BioMarin Pharmaceutical Inc.
Access The Complete Hereditary Angioedema Therapeutics Market Report:
Hereditary Angioedema Therapeutics Market Largest Region By Revenue And Market Share
North America was the largest region in the global hereditary angioedema therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
